Abstract 306P
Background
In developed countries, with advances in chemotherapy treatments cardiovascular diseases (CVD) are a competing cause of morbidity and mortality in early breast cancer (EBC). Within 3 years of chemotherapy completion, heart failure rates in EBC are 3X that of age-matched controls. Psychologic distress is known to negatively affect CVD incidence and prognosis in women. In oncology, distress is termed the ‘6th vital sign’, commonly assessed and reported. Since 2016, electronic entry of Edmonton Symptom Assessment System (ESAS) was phased in Alberta cancer clinics. Accordingly, we searched province-wide administrative databases to examine the potential impact of patient-reported outcome measures (PROMs) on future CVD events in EBC.
Methods
After excluding non-breast cancers, metastatic disease, or research protocol, 3101 EBC cases received chemotherapy from January 1 2016 to December 31 2020. Our primary outcome was a composite of inpatient or outpatient ICD-10 coded CVD events within 3 years of chemotherapy completion. 371 cases had CVD events and ESAS recorded. ESAS PROMs (pain, tiredness, drowsiness, nausea, appetite, dyspnea, depression, anxiety, wellbeing) recorded within 6 months of chemotherapy initiation were assessed.
Results
The data were very similar for inpatient and outpatient groups with total Principal Component Analysis (PCA) 1 35.7 & 38.4, & PCA2 29.8 & 30.4 respectively. The non-parametric comparison for inpatient cases when comparing CVD vs none shows depression is the strongest contributor among the analyzed variables with p-value 0.0089. Outpatient variables, age and HER2 status did not pass the p-value threshold. Table: 306P
Depression | 0.008 |
Anxiety | 0.09 |
Tiredness | 0.13 |
Wellbeing | 0.52 |
Lack Appetite | 0.53 |
Nausea | 0.74 |
Shortness Breath | 0.81 |
Drowsiness | 0.97 |
Pain | 0.97 |
Conclusions
Depression reported early in EBC trajectory is associated with future CVD events requiring hospitalization. This novel finding has implications in assessment and provision of early supportive care. Future work should assess larger datasets and non-CVD events relevant to EBC survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Edith Pituskin.
Funding
Alberta Innovates Precision Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - Relationship between initial tumor burden and the probability of pathological complete response within molecular subtypes of early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 14
260P - Impact of HER2-low status on clinicopathological characteristics and pathological complete response in luminal and triple-negative early breast cancer
Presenter: Katarzyna Pogoda
Session: Poster session 14
261P - Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact
Presenter: Isabel Echavarria Diaz-Guardamino
Session: Poster session 14
262P - Predictive clinico-biological factors of toxicity associated to neo-adjuvant chemo- immunotherapy in early-stage triple-negative breast cancer
Presenter: Elsa Volant
Session: Poster session 14
263P - Association between clinicopathological characteristics and pathological complete response in patients with triple negative breast cancer treated by neoadjuvant chemo-immunotherapy
Presenter: Clara Helal
Session: Poster session 14
264P - Neuropsychological and morphological effects of simultaneous exercise during neo-/adjuvant chemotherapy in breast cancer patients: The Exercise Cancer and Cognition (ECCO) study
Presenter: David Kiesl
Session: Poster session 14
265P - Association of clinical benefit of adjuvant capecitabine and RCB class in triple negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy
Presenter: Shinyoung Lee
Session: Poster session 14
266P - Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial
Presenter: Guillermo Villacampa
Session: Poster session 14
267P - The tumour microenvironment influences long-term tamoxifen treatment response in breast cancer patients
Presenter: Paula Camargo Romera
Session: Poster session 14
268P - Impact of B cell and plasma cell infiltration on survival in early-stage breast cancer (BC) without recurrence
Presenter: Laura Angelats
Session: Poster session 14